 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...2122232425262728293031...132133» |
- ||| everolimus / Generic mfg.
Retrospective data, Review, Journal, Adverse events: mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: a systematic review and meta-analysis. (Pubmed Central) - Sep 22, 2022
Sirolimus and everolimus are mammalian target of rapamycin inhibitors (mTORi) that can reduce relapse rates following liver transplantation (LT) for hepatocellular carcinoma (HCC)...mTORi reduced the recurrence incidence and overall five-year mortality rate but increased many other incidences of AEs compared with that by CNI. Therefore clinicians should be aware of the risks and benefits of mTORi use when managing patients undergoing LT for HCC.
- || amcenestrant (SAR439859) / Sanofi
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: AMEERA-1: Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Sep 22, 2022
P1/2, N=136, Active, not recruiting, Sponsor: Sanofi
Therefore clinicians should be aware of the risks and benefits of mTORi use when managing patients undergoing LT for HCC. Trial completion date: Aug 2024 --> Dec 2023 | Trial primary completion date: Aug 2024 --> Dec 2023
- ||| Trial completion, Trial completion date, Metastases: SAFIR-TOR: Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor (clinicaltrials.gov) - Sep 21, 2022
P=N/A, N=150, Completed, Sponsor: UNICANCER
Trial completion date: Aug 2024 --> Dec 2023 | Trial primary completion date: Aug 2024 --> Dec 2023 Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Jul 2022
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
A phase II study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma (mRCC) that progressed on a PD-1/PD-L1 checkpoint inhibitor (LenCabo) (Poster Hall, Board F3) - Sep 21, 2022 - Abstract #IKCS2022IKCS_139;
P2
PFS will be monitored using Bayesian optimal phase 2 design, and an interim analysis will be performed at 50 patients. The study has enrolled 8 patients to date at 1 US site and will open at 2 additional US sites by February 2023.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Updated efficacy of lenvatinib + pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study (Poster Hall, Board C7) - Sep 21, 2022 - Abstract #IKCS2022IKCS_119;
A large proportion of patients treated with lenvatinib + pembrolizumab completed 2 years of pembrolizumab and continued with lenvatinib monotherapy with ongoing clinical benefit. The results further support lenvatinib + pembrolizumab as a standard of care in 1L aRCC.
- |||||| everolimus / Generic mfg.
Clinical: Great point and relatedly prior adjuvant mTOR inhibitor study was negative but lots of exciting correlatives to come to help us understand pathway #bcsm @SWOG #TumorBoardTuesday S1207: Phase IIl randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endoTx (Twitter) - Sep 20, 2022
- | Opdivo (nivolumab) / Ono Pharma, BMS
Biomarker, Journal, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. (Pubmed Central) - Sep 20, 2022
Both tumor cell-extrinsic (immune-related) and -intrinsic (cell proliferation-related) mechanisms are likely intertwined in the regulation of TC PD-L1 expression in ccRCC. The quantitation of these transcriptional programs may better predict benefit from anti-PD-1-based therapy compared to TC PD-L1 expression alone in ccRCC.
- | everolimus / Generic mfg.
Retrospective data, Journal: ♣Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study. (Pubmed Central) - Sep 20, 2022
The risk stratification model could well distinguish eAML patients at high risk of recurrence/metastasis. Everolimus targeted treatment showed good efficacy in patients with recurrence/metastasis.
- cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg.
The effect of blood pressure increase on the course of pulse wave velocity in pediatric kidney transplant recipients (Poster Area - Exhibition Hall E) - Sep 20, 2022 - Abstract #IPNA2022IPNA_338;
No associations with sex, eGFR or tacrolimus trough level were detected.An alarming surge in arterial stiffness depending on greater BP increases is seen in pediatric KTx recipients. Our data not only points out the central role of adequate BP control in this patient group, but also highlights that controlling modifiable risk factors can improve cardiovascular outcome after KTx.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Ebstein-Barr virus-associated smooth muscle tumor in a boy after kidney transplantation (Poster Area - Exhibition Hall E) - Sep 20, 2022 - Abstract #IPNA2022IPNA_91;
Initial immunosuppression (IS) was achieved with interleukin-2 receptor blocking induction, followed by methylprednisolone, mycophenolate mofetil (MMF), and tacrolimus...He received six cycles of rituximab. MMF was discontinued, and tacrolimus switched to everolimus... The occurrence of SMTs should be considered in pediatric kidney transplant recipients with EBV infection and round sonographic lesions in different organs, particularly in the liver, spleen, and lungs.
- everolimus / Generic mfg.
A case of TSC2/PKD1 contiguous gene syndrome: treatment for neurological complications would improve the management of kidney complications (Poster Area - Exhibition Hall E) - Sep 20, 2022 - Abstract #IPNA2022IPNA_74;
Lately, earlier induction of everolimus has been demonstrated to improve neurological complications of TSC. Treatment for neurological complications by everolimus would improve the management of kidney complications in PKDTS.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., everolimus / Generic mfg.
As of today, the COMPOSE phase III RCT is open at Mayo Clinic in Rochester! PRRT with Lu-177 edotreotide (DOTATOC) vs. CAPTEM, FOLFOX or everolimus for 1st or 2nd line therapy for advanced high-risk G2 NETs (Ki67 15-20%) or well diff G3 NETs ≤ 55%. https://t.co/hnUmPx9Tqo (Twitter) - Sep 16, 2022
- Tagrisso (osimertinib) / AstraZeneca
Out-of-pocket costs for oral anticancer drugs. (Available On Demand; Poster Bd #: A12) - Sep 15, 2022 - Abstract #ASCOQC2022ASCO_QC_107;
Counter to expectations, in some cases generics were more costly than brands, and more pills at a lower dose were less costly than fewer pills. There was no consistent pattern.
- Surgical Outcomes after Cytoreductive Nephrectomy following Neoadjuvant Immunotherapy for Metastatic Renal Cell Carcinoma (NH/VT Room) - Sep 15, 2022 - Abstract #NEAUA2022NEAUA_137;
Our data shows a decrease in the mean size of the renal mass at time of nephrectomy following immunotherapy, making surgery more feasible and possibly less technically challenging. The fact that the 30-day readmission rate is zero emphasizes the short-term safety of this approach.
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Journal: Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience. (Pubmed Central) - Sep 14, 2022
In our experience, the treatment associated with the best OS was everolimus. Despite the small simple size of our study, our data suggest a prognostic advantage and a safe profile of targeted therapies in DIPG patients, and we strongly advocate to reconsider the role of biopsy for these patients.
- || Retrospective data, Review: Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis. (Pubmed Central) - Sep 14, 2022
A total of 12 eligible RCTs involved 1,959 patients and 13 treatments: apatinib, cabozantinib, anlotinib, nintedanib, lenvatinib, lenvatinib with low dose (LD), sorafenib, sorafenib plus everolimus, donafenib (200 mg), donafenib (300 mg), pazopanib (continuous), pazopanib (intermittent), and vandetanib...Patients who received lenvatinib or apatinib also had more grade 3 or higher adverse events. Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=302249], identifier [CRD42022302249].
- | cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg.
Journal: Arterial stiffness and blood pressure increase in pediatric kidney transplant recipients. (Pubmed Central) - Sep 14, 2022
This emphasizes the role of BP as a modifiable risk factor for the improvement of cardiovascular outcome after transplantation. A higher resolution version of the Graphical abstract is available as Supplementary information.
- || cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg.
PK/PD data, Preclinical, Journal: The Immunobiogram, a novel in vitro diagnostic test to measure the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients. (Pubmed Central) - Sep 14, 2022
A higher resolution version of the Graphical abstract is available as Supplementary information. Our results highlight the potential of Immunobiogram as a tool to test the pharmacodynamic response to individual immunosuppressive drugs.
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Immunosuppressed non-responders to two doses of mRNA SARS-CoV-2 vaccines achieve an immune response comparable to those of immunocompetent individuals after a third dose. (Pubmed Central) - Sep 14, 2022
Most non-responders are on treatment with either glucocorticoids, mycophenolate-mofetil (MMF), the anti-CD20 monoclonal antibody rituximab, calcineurin inhibitors like cyclosporine and tacrolimus, rapamycin (mTOR) signaling cascade inhibitors (i.e., sirolimus and everolimus), azathioprine, or methotrexate given for a variety of diseases including autoimmune disorders, hematological malignancies, and solid cancers, while recipients of solid organ transplants also fall within this category. Recently, several published reports have suggested that a third dose of these vaccines induces an elevated antibody response against the SARS-CoV-2 S protein.
- | sirolimus / Generic mfg.
Preclinical, Journal: Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice. (Pubmed Central) - Sep 14, 2022
Immunohistology and immunophenotypic analysis of cells, and quantitative RT-PCR suggested that changes in microglial polarity were involved in the onset of TSC epilepsy and neuropsychiatric symptoms. Although the effect of mTORC1 inhibitors on TAND has not been established, the results of this study might help elucidate the mechanism of TAND pathogenesis and suggest that sirolimus may be a valuable therapeutic tool for TAND.
- | everolimus / Generic mfg.
Retrospective data, Journal: Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients. (Pubmed Central) - Sep 14, 2022
De novo immunosuppression with EVL is associated with attenuated CAV progression for the first 5 years of follow-up via IVUS. Moreover, EVL has comparable long-term clinical outcomes to those of CSA- or TAC-based protocols.
- || Trial completion date, Trial primary completion date, Real-world evidence, Real-world, Metastases: Treat ER+ight: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy (clinicaltrials.gov) - Sep 13, 2022
P=N/A, N=440, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Moreover, EVL has comparable long-term clinical outcomes to those of CSA- or TAC-based protocols. Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Dec 2022
- ||||| everolimus / Generic mfg.
Clinical: 🔥SEQTOR study in neuroendocrine tumors at #ESMO22 🔥 👉141 pts ✅Arm A: everolimus -> streptozotocin: ORR 11%, mPFS1 21.5 m ✅Arm B: streptozotocin -> everolimus: ORR 30%, mPFS2 23.8 m 👉similar, but higher ORR for strepto -> if response is required @myESMO @OncoAlert (Twitter) - Sep 12, 2022
- Welireg (belzutifan) / Merck (MSD)
BELZUTIFAN-INDUCED HYPERSENSITIVITY PNEUMONITIS (Convention Center Exhibit Hall: Poster Area) - Sep 11, 2022 - Abstract #CHEST2022CHEST_3979;
Her cancer diagnosis was established in 2019 and had undergone cytoreductive nephrectomy and treatment with axitinib/pembrolizumab...Due to further disease progression, she was transitioned to lenvatinib/everolimus, though the treatment was discontinued due to anorexia and worsening pulmonary symptoms...She was covered with azithromycin/ceftriaxone along with high-dose steroids and was admitted to the stepdown unit for further management... We report the only known case of Belzutifan-induced hypersensitivity pneumonitis and hope this case will become a useful contribution to the literature.
- everolimus / Generic mfg.
BRONCHOPULMONARY CARCINOID AND TYPE 1 MULTIPLE ENDOCRINE NEOPLASIA (MEN) (Convention Center Exhibit Hall: Rapid Area 4C) - Sep 11, 2022 - Abstract #CHEST2022CHEST_3592;
Bronchopulmonary NETs can be seen in MEN 1, but do not decrease overall survival. However, poorly differentiated and aggressive NETs can lead to death with 10-year survival rates of 59% in atypical carcinoids.
- octreotide acetate solution for injection / Generic mfg., everolimus / Generic mfg.
TYPE 1 MULTIPLE ENDOCRINE NEOPLASIA-ASSOCIATED TRACHEOBRONCHIAL TUMORS MANAGED BY RIGID BRONCHOSCOPY-DIRECTED MULTIMODAL TUMOR DESTRUCTION (Convention Center Exhibit Hall: Rapid Area 3D) - Sep 11, 2022 - Abstract #CHEST2022CHEST_3332;
MEN1 associated with numerous tracheobronchial tumors can cause devastating central airway obstruction. Rigid bronchoscopy with multimodal tumor destruction technique can be a safe and effective option for patients who would not benefit from a surgical approach.
- | Torisel (temsirolimus) / Pfizer
Journal: PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma. (Pubmed Central) - Sep 10, 2022
Of note, PTEN protein loss as detected by immunohistochemistry is much more frequent than mutations in the PTEN gene in ccRCC patients. Our study suggests that PTEN loss correlates with rapalog sensitivity and could be used as a marker for ccRCC patient selection for rapalog therapy.
- | chlorpromazine / Generic mfg., gefitinib / Generic mfg.
Preclinical, Journal: Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. (Pubmed Central) - Sep 10, 2022
However, after CPZ treatment, EGFR was unevenly distributed in the cells, and colocalization with the early endosome marker Rab5 and EEA1 became more apparent, indicating that CPZ disrupted the intracellular transport of EGFR. These results suggest that CPZ has therapeutic potential for NSCLC with mutated EGFR by a novel mechanism different from conventional TKIs alone or in combination with other agents.
- || vepdegestrant (ARV-471) / Arvinas, Pfizer
Enrollment open, Combination therapy, Metastases: TACTIVE-E: ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (clinicaltrials.gov) - Sep 10, 2022
P1b, N=32, Recruiting, Sponsor: Arvinas Estrogen Receptor, Inc.
These results suggest that CPZ has therapeutic potential for NSCLC with mutated EGFR by a novel mechanism different from conventional TKIs alone or in combination with other agents. Not yet recruiting --> Recruiting
- | everolimus / Generic mfg.
Trial completion, Metastases: Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus (clinicaltrials.gov) - Sep 10, 2022
P=N/A, N=45, Completed, Sponsor: Istituto Clinico Humanitas
Not yet recruiting --> Recruiting Unknown status --> Completed
- | everolimus / Generic mfg.
Journal: Neuroendocrine neoplasms of the small intestine and the appendix - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego - uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]. (Pubmed Central) - Sep 7, 2022
After the exhaustion of the above available therapies, chemotherapy may be considered in selected cases. Recommendations for patient monitoring are also presented.
- prednisone / Generic mfg., everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
An Unusual Case of Chronic Rejection Following Liver Transplant Due to Autoantibody Formation During Pregnancy (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_902;
Consistent post-transplant HLA antibody testing should be a consideration for LDLT patients for early detection and treatment of DSA before memory B-cell production allows rejection to become chronic. Testing is especially important for monitoring female patients with LDLTs from spouse due to risk of blood exposure during pregnancy.
- adagrasib (MRTX849) / Mirati, Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci, Lumakras (sotorasib) / Amgen
KRAS G12C mutated NSCLC and bladder cancer xenografts treated with sotorasib and adagrasib in combination with mTOR inhibitors show improved antitumor activity of nab-sirolimus vs everolimus (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_302;
Combining mTOR inhibition with KRAS G12C inhibition improves response against tumors in vivo. nab-Sirolimus showed greater potency compared to everolimus and is the preferred agent for further clinical development using this strategy.
- Avastin (bevacizumab) / Roche, Sutent (sunitinib) / Pfizer
Establishment and characterization of a preclinical platform of subcutaneous renal cell carcinoma (RCC) patient-derived xenograft models to evaluate novel treatment strategies (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_174;
In summary, we report a newly established and molecularly characterized panel of RCC PDX models with high relevance for translational preclinical research. No
- | Journal: Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma. (Pubmed Central) - Sep 3, 2022
The germinal center B-cell like diffuse large B-cell lymphoma (DLBCL) cell lines OCI-LY-19 and WSU-DLCL2 were exposed to 348 compounds given as single agents at two different concentrations and in combination with the BET inhibitor birabresib...The screening identified a series of compounds leading to a stronger antiproliferative activity when given in combination than as single agents: the histone deacetylase (HDAC) inhibitors panobinostat and dacinostat, the mTOR (mechanistic target of rapamycin) inhibitor everolimus, the ABL/SRC (ABL proto-oncogene/SRC proto oncogene) inhibitor dasatinib, the AKT1/2/3 inhibitor MK-2206, the JAK2 inhibitor TG101209...Genetic silencing demonstrated that LRRK2 sustains the proliferation of lymphoma cells, a finding paired with the association between high expression levels and inferior outcome in DLBCL patients. We identified combinations that can improve the response to BET inhibitors in lymphomas, and LRRK2 as a gene essential for lymphomas and as putative novel target for this type of tumors.
- everolimus / Generic mfg.
Preclinical evaluation of a novel everolimus-coated peripheral balloon (Room 114) - Sep 3, 2022 - Abstract #CIRSE2022CIRSE_880;
The preclinical evaluation indicated that the developed ECB is safe in the models examined. Use of the ECB resulted in reduced stenosis rates and lower arterial host reaction and inflammation compared to PCBs.
- | Journal, PD(L)-1 Biomarker, IO biomarker: Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma (Pubmed Central) - Sep 3, 2022
Furthermore, the combination of lenvatinib + everolimus and axitinib are approved treatment options in the second line and further settings...As in previous years, the experts intended to provide recommendations for clinical practice. The results are presented in this publication.
- | everolimus / Generic mfg.
Retrospective data, Journal: Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond. (Pubmed Central) - Sep 2, 2022
Combined retrospective analysis and correlative immunology research revealed that patients receiving everolimus may have derived a greater benefit. The currently enrolling phase 2 CoImmune trial is designed to test this hypothesis in patients undergoing cytoreductive nephrectomy and systemic therapy.
- Piqray (alpelisib) / Novartis
Cost-Effectiveness of Alpelisib Plus Fulvestrant for the Treatment of Postmenopausal Women With PIK3CA Mutant, HR+/HER2- Advanced Breast Cancer in Turkey (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1333;
Comparators were ribociclib+fulvestrant, palbociclib+fulvestrant, fulvestrant, everolimus+exemestane and chemotherapy. Alpelisib+fulvestrant treatment in post-menapousal women with PIK3CA mutant HR+/HER2- advanced breast cancer after prior treatment with an aromatase inhibitor is a cost-effective option in Turkey.
- everolimus / Generic mfg.
Cost-Effectiveness of Everolimus Combination Therapy in Patients After Liver Transplantation Focusing on Cancer Risk: A Markov Model Using Real-World Data (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_846;
Combining EVR with CNI therapy reduced the risk of HCC and extrahepatic cancers in patients who underwent LT. Adding EVR to CNI therapy was more cost-effective than CNI therapy alone at a socially agreed ICER threshold of USD 20,000/QALY.
- | Journal: Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date. (Pubmed Central) - Aug 31, 2022
A new IL-6 blocking drug (clazakizumab/tocilizumab) is promising option for prevention/treatment of AMR. Clinical experience in tailoring immunosuppression for as long as possible graft and patient survival is inevitable.
- || Sutent (sunitinib) / Pfizer
Review, Journal: Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. (Pubmed Central) - Aug 31, 2022
Clinical experience in tailoring immunosuppression for as long as possible graft and patient survival is inevitable. Major advances in the understanding of genetic and epigenetic mechanisms of NET development in the context of inherited endocrine disorders have led to the recognition of molecular targetable alterations, providing a rationale for the implementation of treatments and development of novel targeted therapies.
- | everolimus / Generic mfg.
Journal: Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival. (Pubmed Central) - Aug 31, 2022
This report highlights that patients with pancreatic neuroendocrine neoplasms have a potential risk of recurrence even after 5 years of recurrence-free survival. In addition, combined aggressive hepatectomy and continuous medication can contribute dramatically to long-term survival even for late-stage recurrence of liver metastases.
- | bortezomib / Generic mfg., everolimus / Generic mfg.
Journal: Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells. (Pubmed Central) - Aug 31, 2022
The combination of everolimus and bortezomib demonstrated a synergistic effect against OS both in vitro and in vivo. These results indicate that this combination may be useful as a novel therapeutic strategy for OS.
- | everolimus / Generic mfg.
Journal: Tuberous sclerosis complex with skin lesions as the initial presentation: A case report and multidisciplinary discussion. (Pubmed Central) - Aug 31, 2022
After consultation by the multidisciplinary team of tuberous sclerosis complex, the patient was treated with everolimus orally and followed up regularly...Early intervention can prolong the life of patients and improve their life quality. Multidisciplinary collaboration for lifelong disease management is the key to enhance the diagnosis and treatment for tuberous sclerosis complex and enhance the prognosis of patients.
- | sunitinib / Generic mfg.
Enrollment open, Metastases: TARGETMONITO: TARGETed Therapy Drug MONITOring in DIGestive Oncology (clinicaltrials.gov) - Aug 31, 2022
P=N/A, N=330, Recruiting, Sponsor: UNICANCER
Multidisciplinary collaboration for lifelong disease management is the key to enhance the diagnosis and treatment for tuberous sclerosis complex and enhance the prognosis of patients. Not yet recruiting --> Recruiting
- |||||||||| Fruzaqla (fruquintinib) / Takeda
New P2/3 trial, Combination therapy, Metastases: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) (clinicaltrials.gov) - Aug 30, 2022
P2/3, N=264, Not yet recruiting, Sponsor: Hutchison Medipharma Limited
- || Ibrance (palbociclib) / Pfizer
Trial completion, Combination therapy, Metastases: Palbociclib With Everolimus + Exemestane In BC (clinicaltrials.gov) - Aug 29, 2022
P1b/2a, N=41, Completed, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Journal: A Biocompatible 4D Printing Shape Memory Polymer as Emerging Strategy for Fabrication of Deployable Medical Devices. (Pubmed Central) - Aug 28, 2022
A 4D printing stent with deformable shape and recovery at temperature close to human body temperature demonstrated the potential application as DMD. In addition, the everolimus was loaded to the polymer (ps1-PCL) through host-guest coordination with ?-cyclodextrin as the core of the star polymer, which showed sustain drug releasing and improved body's inflammatory response.
- | cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg.
Journal: PLA-PEG Implant as a Drug Delivery System in Glaucoma Surgery: Experimental Study. (Pubmed Central) - Aug 27, 2022
In addition, the everolimus was loaded to the polymer (ps1-PCL) through host-guest coordination with ?-cyclodextrin as the core of the star polymer, which showed sustain drug releasing and improved body's inflammatory response. Prolonged delivery of either cyclosporine A or everolimus by means of PLA-PEG implants represents a promising strategy of wound healing modulation in glaucoma filtration surgery.